Market Intelligence, Clinical Progress, and High-Purity Reagents for Immune Checkpoint Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HLA-G drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HLA-G/B2M Monomer & Disulfide-Linked Dimer Complex High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. HEK293 Expressed. |
View HLA-G Products |
| Gene Delivery | HLA-G Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and surface expression assays. |
View HLA-G Products |
| Benchmark Ab | Anti-HLA-G Recombinant Antibody (Sequence of TTX-080) Recombinant positive control for blocking and binding assays. |
View HLA-G Products |
| Validator | HLA-G siRNA Set For target knockdown verification in functional cell assays. |
View HLA-G Products |
| Related Target A | LILRB1 (ILT2) Primary inhibitory receptor on NK and T cells; binds dimeric HLA-G with high affinity. |
View LILRB1 Products |
| Related Target B | LILRB2 (ILT4) Myeloid-expressed inhibitory receptor; mediates HLA-G-induced immunosuppression. |
View LILRB2 Products |
| Related Target C | KIR2DL4 (CD158d) Endosomal/surface receptor on NK cells interacting with HLA-G. |
View KIR2DL4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Dimer vs. Monomer differentiation | Disulfide-linked dimer and monomeric HLA-G/B2M complexes available, verified by SDS-PAGE and SEC-MALS. |
| Cross-reactivity with classical HLA Class I | Counter-screening panels including recombinant HLA-A, HLA-B, and HLA-C proteins strictly sequence-verified. |
| Lack of Controls | Clinical Benchmark Antibodies (TTX-080 biosimilar) included for functional assay validation. |
| False Positives | Validated siRNA included for specificity checks in target-expressing cancer cell lines. |
Live HLA-G R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HLA-G therapeutics is intensifying, with major players shifting focus from traditional immune checkpoint inhibitors (like PD-1/PD-L1) to novel myeloid and NK cell-targeted checkpoints. As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific blocking of HLA-G dimers, which exhibit significantly higher affinity for LILRB1 (ILT2) than monomers, without disrupting classical HLA-mediated antigen presentation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Tizona Therapeutics, AbbVie | Solid Tumors (CRC, NSCLC, Ovarian) | Blocking Assay (Need high-purity HLA-G dimer & LILRB1/2 proteins) |
| Bispecific Antibody | Academic Institutes, Biotech Startups | Hematological Malignancies, Solid Tumors | Dual-binding validation (Need recombinant HLA-G and CD3/TAA antigens) |
| Antibody-Drug Conjugate (ADC) | Emerging Biopharma | HLA-G highly expressed metastatic cancers | Internalization Assay (Need Lentivirus for stable cell line construction) |